3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
64
Neoplasm Metastasis
14
Brain Neoplasms
10
Neoplasms
9
Endometrial Neoplasms
8
Prostatic Neoplasms
7
Glioblastoma
7
Ovarian Neoplasms
6
Triple Negative Breast Neoplasms
5
Glioma
5
Sarcoma
3
Recurrence
3
Neoplasms by Site
3
Meningioma
3
Carcinoma, Non-Small-Cell Lung
3
Breast Diseases
3
Unilateral Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma, Ewing
2
Osteosarcoma
2
Liposarcoma
2
Head and Neck Neoplasms
2
Fallopian Tube Neoplasms
2
Ependymoma
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Renal Cell
2
Advanced Breast Cancer
2
Uterine Cervical Neoplasms
1
Urogenital Neoplasms
1
Interventions
Letrozole
5
Fulvestrant
5
trastuzumab deruxtecan
3
Injections
3
toripalimab
2
sacituzumab govitecan
2
palbociclib
2
elacestrant
2
abemaciclib
2
Anastrozole
2
AZD9833
2
ribociclib
1
pyrotinib
1
exemestane
1
eribulin
1
disitamab vedotin
1
dalpiciclib
1
Vinorelbine
1
Selective Estrogen Receptor Modulators
1
Ritonavir
1
RAD1901
1
Paclitaxel
1
Lead
1
Itraconazole
1
Goserelin
1
Gonadotropin-Releasing Hormone
1
Everolimus
1
Docetaxel
1
Bevacizumab
1
Aromatase Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Advanced Breast Cancer
×
abemaciclib
×
1 year
×
Clear all
NCT06380751
2026-05-15
EvoPAR-BR01
AstraZeneca
Phase 3
Recruiting
500 enrolled
NCT04227327
2025-07-29
HERMIONE-7
University of Milano Bicocca
Phase 2
Terminated
31 enrolled